Guardant Health, Inc. $GH Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Guardant Health, Inc. (NASDAQ:GH) by 6.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 71,236 shares of the company’s stock after purchasing an additional 4,056 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.06% of Guardant Health worth $3,035,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. SVB Wealth LLC acquired a new position in Guardant Health in the first quarter valued at $54,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Guardant Health in the fourth quarter valued at $61,000. GF Fund Management CO. LTD. acquired a new position in Guardant Health in the fourth quarter valued at $79,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Guardant Health in the first quarter valued at $97,000. Finally, CWM LLC increased its stake in Guardant Health by 180.3% in the first quarter. CWM LLC now owns 2,296 shares of the company’s stock valued at $98,000 after purchasing an additional 1,477 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Stock Performance

Shares of GH opened at $54.90 on Friday. The company has a market capitalization of $6.85 billion, a P/E ratio of -16.39 and a beta of 1.46. Guardant Health, Inc. has a one year low of $20.14 and a one year high of $68.00. The stock has a 50-day moving average price of $53.81 and a 200 day moving average price of $47.65.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.08. The business had revenue of $232.09 million during the quarter, compared to analysts’ expectations of $211.19 million. During the same period in the prior year, the company posted ($0.84) EPS. The company’s revenue for the quarter was up 31.0% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Activity at Guardant Health

In other Guardant Health news, Director Ian T. Clark sold 6,672 shares of the stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $48.38, for a total transaction of $322,791.36. Following the transaction, the director owned 9,851 shares of the company’s stock, valued at $476,591.38. This trade represents a 40.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Amirali Talasaz sold 100,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $50.88, for a total value of $5,088,000.00. Following the transaction, the chief executive officer directly owned 1,971,830 shares in the company, valued at approximately $100,326,710.40. This represents a 4.83% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 412,921 shares of company stock worth $23,558,346 over the last quarter. 6.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on GH. Evercore ISI raised Guardant Health to a “strong-buy” rating in a research report on Monday, July 14th. Mizuho boosted their price target on Guardant Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Friday, June 13th. Raymond James Financial boosted their price target on Guardant Health from $59.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, July 31st. BTIG Research boosted their price target on Guardant Health from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, September 4th. Finally, Scotiabank upped their target price on Guardant Health from $57.00 to $60.00 and gave the stock a “sector outperform” rating in a research report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $58.24.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.